Danyliuk M. B., Zavgorodniy S. M., Kubrak M. A., Fedotov E. R., Mikhalchenko E. K., Shchurov M. F.

SEARCHING FOR ASTHENIC SYNDROME MARKERS IN ELDERLY AND OLD AGE PATIENTS WITH ACUTE CHOLECYSTITIS

---

Show/Download

About the author:

Danyliuk M. B., Zavgorodniy S. M., Kubrak M. A., Fedotov E. R., Mikhalchenko E. K., Shchurov M. F.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The population of our planet is constantly aging, and every year there are more and more elderly patients. However, regardless of the primary pathology with which the patient goes to the medical institution, people of this age category have several concomitant pathologies that significantly affect treatment results. One of the influential factors is the syndrome of senile asthenia, which is currently quite studied, but there are still no reliable markers, and the main searches are actively continuing. The work is based on diagnosing markers of acute and chronic inflammatory processes in elderly and senile patients. The total number of patients was 60 (100.0%). To conduct the study, we included 30 (50.0%) patients who were examined in the polyclinic of this hospital and in whom no acute surgical pathology was detected – group A. The basis of the work included 15 (25.0%) patients with acute cholecystitis and the detected syndrome of senile asthenia - group B and 15 (25.0%) patients with acute cholecystitis without the syndrome of senile asthenia – group C. In all 60 (100.0%) patients, senile asthenia syndrome was diagnosed using the Edmonton Freil scale chosen by us. Based on the analysis of literature data and our research, to find reliable markers of senile asthenia, we analyzed the value of the total number of leukocytes in the blood; C-reactive protein and interleukin 6 were also included in the study. Our research has determined that IL-6 and CRP levels can be markers of chronic and acute inflammation in asthenic syndrome in elderly patients. In the acute inflammatory process due to cholecystitis in asthenic syndrome in elderly patients, the degree of growth of CRP and the absolute number of lymphocytes is determined by the degree of growth of IL-6 as a primary marker of aging.

Tags:

Bibliography:

1. Keevil VL, Romero-Ortuno R. Ageing well: a review of sarcopenia and frailty. Proc Nutr Soc. 2015;74(4):337-47. DOI: 10.1017/ S0029665115002037.
2. Bibas L, Levi M, Bendayan M, Mullie L, Forman DE, Afilano J, et al. Therapeutic interventions for frail elderly patients: part I. Published randomized trials. Prog Cardiovasc Dis. 2014;57(2):134-43. DOI: 10.1016/j. pcad.2014.07.004.
3. Webb J, Gerosa G, Lefevre T, Leipsic J, Spence M, Thomas M, et al. Multicenter evaluation of a nextgeneration balloon-expandable transcatheter aortic valve. JACC. 2014;64(21):2235-43. DOI: 10.1016/j.jacc.2014.09.026.
4. Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green Ph, Allen LA, et al. Frailty assessment in the cardiovascular care of older adults. JACC. 2014;63(8):747-62. DOI: 10.1016/j.jacc.2013.09.070.
5. Finn M, Green P. The Influence of Frailty on Outcomes in cardiovascular Disease. Rev Esp Cardiol (Engl Ed). 2015;68(8):653. DOI: 10.1016/j.rec. 2015.04.005.
6. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):146-56.
7. Didoha IV. Efektyvnist korektsiyi fizychnoho statusu khvorykh z komorbidnistyu khvoroby parkinsona ta starechoyi asteniyi zasobamy fizychnoyi terapiyi yak peredumovy obmezhennya aktyvnostey povsyakdennoho zhyttya. Ukrainian Journal of Medicine, Biology and Sports. 2022;5(39):210-218. DOI: 10.26693/jmbs07.05.219. [in Ukrainian].
8. Villacampa-Fernandez P, Navarro-Pardo E, Tarin JJ, Cano A. Frailty and multimorbidity: two related yet different concepts. Maturitas. 2017;95:31-5. DOI: 10.1016/j.maturitas.2016.10.008.
9. National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management. NG56. London: NICE; 2016. Available from: https://www.nice.org.uk/guidance/ng56.
10. Danyliuk MB, Zavgorodniy SM, Yareshko NO, Bachurin AV. Otsinyuvannya syndromu starechoyi asteniyi za dopomohoyu shkaly Frailty ta Edmonton frail u patsiyentiv pokhyloho ta starechoho viku v nevidkladniy abdominalʹniy khirurhiyi. Modern medical technology. 2023;3:12- 17. DOI: 10.34287/MMT.3(58).2023.2. [in Ukrainian].
11. Keenan LG, O’Brien M, Ryan T, Dunne M, McArdle O. Assessment of older patients with cancer: Edmonton Frail Scale (EFS) as a predictor of adverse outcomes in older patients undergoing radiotherapy. Journal of Geriatric Oncology. 2017;8(3):206-210. DOI: https:// doi.org/10.1016/j.jgo.2016.12. 006.
12. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, et al. The origins of age-related proinflammatory state. Blood. 2005;105(6):2294-9. DOI: 10.1182/blood-2004-07-2599.
13. Sansoni P, Vescovini R, Fagnoni F, Biasini C, Zanni F, Zanlari L, et al. The immune system in extreme longevity. Exp Gerontol. 2008;43(2):61- 5. DOI: 10.1016/j.exger.2007.06.008.
14. Bruunsgaard H, Ladelund S, Pedersen AN, Schroll M, Jorgensen T, Pedersen BK. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol. 2003;132(1):24-31. DOI: 10.1046/j.1365-2249.2003.02137.x.
15. Giovannini S, Onder G, Liperoti R, Russo A, Carter Ch, Capoluongo E, et al. Interleukin-6, C-reactive protein, and tumor necrosis factoralpha as predictors of mortality in frail, community-living elderly individuals. J Am Geriatr Soc. 2011;59(9):1679-85. DOI: 10.1111/j.1532- 5415.2011.03570.x.
16. Bruunsgaard H. Effects of tumor necrosis factor-α and interleukin-6 in elderly populations. Eur Cytokine Netw. 2002;13(4):389-91.
17. Minciullo PL, Catalano A, Mandraffino G, Casciaro M, Crucitti A, Maltese G, et al. Inflammaging and AntiInflammaging: The role of cytokines in extreme longevity. Arch Immunol Ther Exp. 2016;64(2):111-26. DOI: 10.1007/s00005-015-0377-3.
18. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006;61(6):575-84. DOI: 10.1093/gerona/61.6.575.
19. Mauer J, Denson JL, Brüning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 2015;36(2):92-101. DOI: 10.1016/j.it.2014. 12.008.
20. Tanaka T, Narazaki M, Kishimoto T. Il-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):016295. DOI: 10.1101/cshperspect.a016295.
21. Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019;20(23):6008. DOI: 10.3390/ijms20236008.
22. Narazaki M, Kishimoto T. The Two-Faced Cytokine IL-6 in host defense and diseases. Int J Mol Sci. 2018;19(11):3528. DOI: 10.3390/ ijms19113528.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 2, 173, 205-213 pages, index UDC 616-009.17:616.366-002-036.11]-053.9-07:577.112

DOI:

10.29254/2077-4214-2024-2-173-205-213